5-HT 2A receptors modulate dopamine D 2 -mediated maternal effects

Jun Gao, Leilei Chen, Ming Li

Research output: Contribution to journalArticle

Abstract

Serotonin 5-HT 2A receptors are expressed throughout the mesolimbic and mesocortical dopamine pathways, and manipulation of this receptor system has a profound impact on dopamine functions and dopamine-mediated behaviors. It is highly likely that 5-HT 2A receptors may also modulate the D 2 -mediated maternal effects. The present study investigated this issue and also explored the possible behavioral mechanisms. We tested the effects of two D 2 drugs (an agonist quinpirole: 0.5, 1.0 mg/kg, and a potent D 2 antagonist haloperidol: 0.05, 0.10 mg/kg, sc) and their combinations with two 5-HT 2A drugs (a selective 5-HT 2A agonist TCB-2: 2.5 mg/kg, and 5-HT 2A antagonist MDL100907, 1.0 mg/kg, sc) on maternal behavior in Sprague-Dawley postpartum females. Individually, TCB-2 (2.5 mg/kg, sc) and quinpirole (0.5 and 1.0 mg/kg, sc) reduced pup preference and disrupted home-cage maternal behavior. In contrast, haloperidol (0.10 mg/kg, sc) only disrupted home-cage maternal behavior, but did not suppress pup preference. MDL100907 (1.0 mg/kg, sc) by itself had no effect on either pup preference or maternal behavior. When administered in combination, pretreatment of TCB-2 did not alter quinpirole's disruption of pup preference and home-cage maternal behavior (possibly due to the floor effect), however, it did enhance haloperidol's disruption of pup retrieval in the home cage. MDL100907 had no effect both quinpirole's and haloperidol's disruption of pup preference and home-cage maternal behavior. Interestingly, haloperidol attenuated TCB-2's disruptive effect on pup preference. These findings suggest that activation of 5-HT 2A receptors tends to enhance D 2 -mediated maternal disruption, whereas blockade of 5-HT 2A receptors is less effective. They also suggest that 5-HT 2A receptors may have a direct effect on maternal behavior independent of their interaction with D 2 receptors. The possible behavioral and neural mechanisms by which 5-HT 2A - and D2-mediated maternal effects and their interaction are discussed.

Original languageEnglish (US)
Pages (from-to)32-43
Number of pages12
JournalPharmacology Biochemistry and Behavior
Volume180
DOIs
StatePublished - May 1 2019

Fingerprint

Receptor, Serotonin, 5-HT2A
Maternal Behavior
Quinpirole
Haloperidol
Dopamine
Serotonin
Pharmaceutical Preparations
Serotonin Receptor Agonists
Serotonin Antagonists
Chemical activation
Maternal Inheritance
Postpartum Period
Mothers

Keywords

  • Dopamine D receptor
  • Emotional processing
  • Incentive motivation
  • Maternal behavior
  • Pup preference
  • Serotonin 2A receptor

ASJC Scopus subject areas

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Clinical Biochemistry
  • Biological Psychiatry
  • Behavioral Neuroscience

Cite this

5-HT 2A receptors modulate dopamine D 2 -mediated maternal effects . / Gao, Jun; Chen, Leilei; Li, Ming.

In: Pharmacology Biochemistry and Behavior, Vol. 180, 01.05.2019, p. 32-43.

Research output: Contribution to journalArticle

@article{4ed57c58821f4ca6ab78107d71c80992,
title = "5-HT 2A receptors modulate dopamine D 2 -mediated maternal effects",
abstract = "Serotonin 5-HT 2A receptors are expressed throughout the mesolimbic and mesocortical dopamine pathways, and manipulation of this receptor system has a profound impact on dopamine functions and dopamine-mediated behaviors. It is highly likely that 5-HT 2A receptors may also modulate the D 2 -mediated maternal effects. The present study investigated this issue and also explored the possible behavioral mechanisms. We tested the effects of two D 2 drugs (an agonist quinpirole: 0.5, 1.0 mg/kg, and a potent D 2 antagonist haloperidol: 0.05, 0.10 mg/kg, sc) and their combinations with two 5-HT 2A drugs (a selective 5-HT 2A agonist TCB-2: 2.5 mg/kg, and 5-HT 2A antagonist MDL100907, 1.0 mg/kg, sc) on maternal behavior in Sprague-Dawley postpartum females. Individually, TCB-2 (2.5 mg/kg, sc) and quinpirole (0.5 and 1.0 mg/kg, sc) reduced pup preference and disrupted home-cage maternal behavior. In contrast, haloperidol (0.10 mg/kg, sc) only disrupted home-cage maternal behavior, but did not suppress pup preference. MDL100907 (1.0 mg/kg, sc) by itself had no effect on either pup preference or maternal behavior. When administered in combination, pretreatment of TCB-2 did not alter quinpirole's disruption of pup preference and home-cage maternal behavior (possibly due to the floor effect), however, it did enhance haloperidol's disruption of pup retrieval in the home cage. MDL100907 had no effect both quinpirole's and haloperidol's disruption of pup preference and home-cage maternal behavior. Interestingly, haloperidol attenuated TCB-2's disruptive effect on pup preference. These findings suggest that activation of 5-HT 2A receptors tends to enhance D 2 -mediated maternal disruption, whereas blockade of 5-HT 2A receptors is less effective. They also suggest that 5-HT 2A receptors may have a direct effect on maternal behavior independent of their interaction with D 2 receptors. The possible behavioral and neural mechanisms by which 5-HT 2A - and D2-mediated maternal effects and their interaction are discussed.",
keywords = "Dopamine D receptor, Emotional processing, Incentive motivation, Maternal behavior, Pup preference, Serotonin 2A receptor",
author = "Jun Gao and Leilei Chen and Ming Li",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.pbb.2019.03.003",
language = "English (US)",
volume = "180",
pages = "32--43",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - 5-HT 2A receptors modulate dopamine D 2 -mediated maternal effects

AU - Gao, Jun

AU - Chen, Leilei

AU - Li, Ming

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Serotonin 5-HT 2A receptors are expressed throughout the mesolimbic and mesocortical dopamine pathways, and manipulation of this receptor system has a profound impact on dopamine functions and dopamine-mediated behaviors. It is highly likely that 5-HT 2A receptors may also modulate the D 2 -mediated maternal effects. The present study investigated this issue and also explored the possible behavioral mechanisms. We tested the effects of two D 2 drugs (an agonist quinpirole: 0.5, 1.0 mg/kg, and a potent D 2 antagonist haloperidol: 0.05, 0.10 mg/kg, sc) and their combinations with two 5-HT 2A drugs (a selective 5-HT 2A agonist TCB-2: 2.5 mg/kg, and 5-HT 2A antagonist MDL100907, 1.0 mg/kg, sc) on maternal behavior in Sprague-Dawley postpartum females. Individually, TCB-2 (2.5 mg/kg, sc) and quinpirole (0.5 and 1.0 mg/kg, sc) reduced pup preference and disrupted home-cage maternal behavior. In contrast, haloperidol (0.10 mg/kg, sc) only disrupted home-cage maternal behavior, but did not suppress pup preference. MDL100907 (1.0 mg/kg, sc) by itself had no effect on either pup preference or maternal behavior. When administered in combination, pretreatment of TCB-2 did not alter quinpirole's disruption of pup preference and home-cage maternal behavior (possibly due to the floor effect), however, it did enhance haloperidol's disruption of pup retrieval in the home cage. MDL100907 had no effect both quinpirole's and haloperidol's disruption of pup preference and home-cage maternal behavior. Interestingly, haloperidol attenuated TCB-2's disruptive effect on pup preference. These findings suggest that activation of 5-HT 2A receptors tends to enhance D 2 -mediated maternal disruption, whereas blockade of 5-HT 2A receptors is less effective. They also suggest that 5-HT 2A receptors may have a direct effect on maternal behavior independent of their interaction with D 2 receptors. The possible behavioral and neural mechanisms by which 5-HT 2A - and D2-mediated maternal effects and their interaction are discussed.

AB - Serotonin 5-HT 2A receptors are expressed throughout the mesolimbic and mesocortical dopamine pathways, and manipulation of this receptor system has a profound impact on dopamine functions and dopamine-mediated behaviors. It is highly likely that 5-HT 2A receptors may also modulate the D 2 -mediated maternal effects. The present study investigated this issue and also explored the possible behavioral mechanisms. We tested the effects of two D 2 drugs (an agonist quinpirole: 0.5, 1.0 mg/kg, and a potent D 2 antagonist haloperidol: 0.05, 0.10 mg/kg, sc) and their combinations with two 5-HT 2A drugs (a selective 5-HT 2A agonist TCB-2: 2.5 mg/kg, and 5-HT 2A antagonist MDL100907, 1.0 mg/kg, sc) on maternal behavior in Sprague-Dawley postpartum females. Individually, TCB-2 (2.5 mg/kg, sc) and quinpirole (0.5 and 1.0 mg/kg, sc) reduced pup preference and disrupted home-cage maternal behavior. In contrast, haloperidol (0.10 mg/kg, sc) only disrupted home-cage maternal behavior, but did not suppress pup preference. MDL100907 (1.0 mg/kg, sc) by itself had no effect on either pup preference or maternal behavior. When administered in combination, pretreatment of TCB-2 did not alter quinpirole's disruption of pup preference and home-cage maternal behavior (possibly due to the floor effect), however, it did enhance haloperidol's disruption of pup retrieval in the home cage. MDL100907 had no effect both quinpirole's and haloperidol's disruption of pup preference and home-cage maternal behavior. Interestingly, haloperidol attenuated TCB-2's disruptive effect on pup preference. These findings suggest that activation of 5-HT 2A receptors tends to enhance D 2 -mediated maternal disruption, whereas blockade of 5-HT 2A receptors is less effective. They also suggest that 5-HT 2A receptors may have a direct effect on maternal behavior independent of their interaction with D 2 receptors. The possible behavioral and neural mechanisms by which 5-HT 2A - and D2-mediated maternal effects and their interaction are discussed.

KW - Dopamine D receptor

KW - Emotional processing

KW - Incentive motivation

KW - Maternal behavior

KW - Pup preference

KW - Serotonin 2A receptor

UR - http://www.scopus.com/inward/record.url?scp=85063315000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063315000&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2019.03.003

DO - 10.1016/j.pbb.2019.03.003

M3 - Article

VL - 180

SP - 32

EP - 43

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

ER -